In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
Tigecycline is the first glycylcycline antimicrobial in phase III clinical trials. This study compares the in vitro activity of tigecycline to 12 other predominately broad-spectrum antimicrobials against 3049 recent inpatient isolates from 38 clinical centers in 17 countries. The minimum concentration at which tigecycline inhibited 90% of the isolates for the entire collection, excluding Pseudomonas aeruginosa, was 1 microg/mL, including vancomycin-resistant enterococci-, extended-spectrum beta-lactamase-, and methicillin-resistant Staphylococcus aureus-resistant phenotypes.
Bouchillon
Samuel K
SK
Laboratories International for Microbiology Studies, Schaumburg, IL 60179, USA. sbouchillon@ihmainc.com
Hoban
Daryl J
DJ
Johnson
Brian M
BM
Stevens
Tim M
TM
Dowzicky
Michael J
MJ
Wu
David H
DH
Bradford
Patricia A
PA
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D005060:Europe; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D016905:Gram-Negative Bacterial Infections / Q000382:microbiology; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D008877:Middle East; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology*; D013019:South Africa; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline